Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(9):1115–1121. doi: 10.1038/bjc.1996.214

Will the Scottish Cancer Target for the year 2000 be met? The use of cancer registration and death records to predict future cancer incidence and mortality in Scotland.

L Sharp 1, R J Black 1, C S Muir 1, I Gemmell 1, A R Finlayson 1, E F Harkness 1
PMCID: PMC2074396  PMID: 8624273

Abstract

Cancer mortality data reflect disease incidence and the effectiveness of treatment. Incidence data, however, reflect the burden of disease in the population and indicate the need for prevention measures, diagnostic services and cancer treatment facilities. Monitoring of targets mandates that both be considered. The Scottish Cancer Target, established in 1991, proposed that a reduction of 15% in mortality from cancer in the under-65s should be achieved between 1986 and 2000. Each year in Scotland approximately 8300 persons under 65 are diagnosed with cancer and 4500 die from the disease. The most common malignancies, in terms of both incident cases and deaths, in the under-65s, are lung and large bowel cancer in males, and breast, large bowel and lung cancer in females. A decrease of 6% in the number of cancer cases diagnosed in males under 65 is predicted between 1986 and 2000, whereas the number of cases in females in the year 2000 is expected to remain at the 1986 level. In contrast, substantial reductions in mortality are expected for both sexes: 17% and 25% in males and females respectively. Demographic changes will influence the numbers of cancer cases and deaths in the Scottish population in the year 2000. However, long-term trends in the major risk factors, such as smoking, are likely to be the most important determinants of the future cancer burden.

Full text

PDF
1115

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker D. J. Time trends in cancer mortality in England and Wales. Br Med J (Clin Res Ed) 1984 May 5;288(6427):1325–1326. doi: 10.1136/bmj.288.6427.1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boyle P., Kaye S. B., Robertson A. G. Changes in testicular cancer in Scotland. Eur J Cancer Clin Oncol. 1987 Jun;23(6):827–830. doi: 10.1016/0277-5379(87)90286-0. [DOI] [PubMed] [Google Scholar]
  3. Boyle P., Soukop M., Scully C., Robertson A. G., Burns H. J., Gillis C. R., Kaye S. B. Improving prognosis of Hodgkin's disease in Scotland. Eur J Cancer Clin Oncol. 1988 Feb;24(2):229–234. doi: 10.1016/0277-5379(88)90258-1. [DOI] [PubMed] [Google Scholar]
  4. Clayton D., Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med. 1987 Jun;6(4):449–467. doi: 10.1002/sim.4780060405. [DOI] [PubMed] [Google Scholar]
  5. Gillis C. R., Hole D. J., Still R. M., Davis J., Kaye S. B. Medical audit, cancer registration, and survival in ovarian cancer. Lancet. 1991 Mar 9;337(8741):611–612. doi: 10.1016/0140-6736(91)91673-i. [DOI] [PubMed] [Google Scholar]
  6. Harding M. J., Paul J., Gillis C. R., Kaye S. B. Management of malignant teratoma: does referral to a specialist unit matter? Lancet. 1993 Apr 17;341(8851):999–1002. doi: 10.1016/0140-6736(93)91082-w. [DOI] [PubMed] [Google Scholar]
  7. Hawkins M. M. Long term survival and cure after childhood cancer. Arch Dis Child. 1989 Jun;64(6):798–807. doi: 10.1136/adc.64.6.798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Junor E. J., Hole D. J., Gillis C. R. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer. 1994 Aug;70(2):363–370. doi: 10.1038/bjc.1994.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Karjalainen S. Geographical variation in cancer patient survival in Finland: chance, confounding, or effect of treatment? J Epidemiol Community Health. 1990 Sep;44(3):210–214. doi: 10.1136/jech.44.3.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Karjalainen S., Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ. 1989 Oct 28;299(6707):1069–1072. doi: 10.1136/bmj.299.6707.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lung M. L., Lam W. P., Chan K. H., Li S., Sham J., Choy D. Direct detection of Epstein-Barr virus in peripheral blood and comparison of Epstein-Barr virus genotypes present in direct specimens and lymphoblastoid cell lines established from nasopharyngeal carcinoma patients and healthy carriers in Hong Kong. Int J Cancer. 1992 Sep 9;52(2):174–177. doi: 10.1002/ijc.2910520203. [DOI] [PubMed] [Google Scholar]
  12. Macgregor J. E., Campbell M. K., Mann E. M., Swanson K. Y. Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. BMJ. 1994 May 28;308(6941):1407–1411. doi: 10.1136/bmj.308.6941.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McArdle C. S., Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ. 1991 Jun 22;302(6791):1501–1505. doi: 10.1136/bmj.302.6791.1501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Robertson C., Boyle P. Age, period and cohort models: the use of individual records. Stat Med. 1986 Sep-Oct;5(5):527–538. doi: 10.1002/sim.4780050517. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES